RXi Pharmaceuticals granted US Notice of Allowance for technology platform RXi Pharmaceuticals received the Notice of Allowance from the USPTO on its novel, self-delivering RNAi platform. The patent broadly covers both the composition and methods of use of RXi's self-delivering platform technology. The patent, once issued, will be scheduled to expire in 2029.
News For RXII From The Last 14 Days
Check below for free stories on RXII the last two weeks.